Selenium supplementation reduces autoantibody concentrations in patients with Hashimoto's thyroiditis and lowers disease activity, Dr. Barbara Gasnier reported at the annual meeting of the Endocrine Society.
Results of a randomized placebo-controlled pilot study involving 72 women with Hashimoto's thyroiditis suggest moderate-level selenium supplementation may be a low-cost, safe, and effective new therapy that curbs progression of this common autoimmune disease, according to Dr. Gasnier of the University of Munich.
Half of the patients were randomized to 200 [micro]g/day of sodium selenite for 3 months; the other half got placebo. All participants received levothyroxine sufficient to maintain their TSH levels within the normal range.
At baseline, all patients had thyroid peroxidase and/or antithyroglobulin antibody levels in excess of 350 U/mL. After 3 months, thyroid peroxidase autoantibody levels were down by 49% in the selenium group, compared with a 10% reduction in the controls. Nine selenium-treated patients and two controls had normal thyroid antibody titers. Antithyroglobulin antibody concentrations remained unchanged in both groups, as did mean TSH, free [T.sub.4], and free [T.sub.3] levels.
Selenium is an essential nutrient with antioxidant properties.
COPYRIGHT 2001 International Medical News Group
COPYRIGHT 2001 Gale Group